BioPorto

Board/Management Information • Oct 30, 2013

Mr. Otto Rasmussen is appointed new CFO as per January 1, 2014 and will be part
of the executive management team. He replaces CFO Frank Harder, who resigned at
his own request. Mr. Otto Rasmussen comes from a position as Senior Finance
Director at Novozymes and has been at Novozymes for a number of years and
before that at Novo Nordisk. Mr. Otto Rasmussen holds an MSc in accounting from
the University of Southern Denmark, a CPA (certified public accountant) from
New Jersey and management training from Harvard.

In addition, Mr. Finn Fjorder was appointed Executive Vice President of Sales
on October 1, 2013. Mr. Finn Fjorder has 18 years of experience in the med-tech
industry at home and abroad, most recently at Pnn Medical and before that at
Medtronic. Mr. Finn Fjorder holds an MSc in chemistry from the Techincal
University of Denmark, supplemented by management training from Copenhagen
Business School.

Mr. Peter Mørch Eriksen, CEO of BioPorto A/S, commented: ‘I am delighted that
we can strengthen BioPorto with two new key members of management, each of
which comes with relevant experience and a clear interest in developing this
company into a success. Otto already solves tasks for us on an interim basis
and it bodes well for our future cooperation. Finn has the experience we need
in the planned execution of the new strategy for increased sales and more
efficient marketing of BioPorto’s product portfolio.’

For further information please contact:

Christina Thomsen, Investor Relations

Telefon 45 29 00 00, mail investor@bioporto.com